Aarti Drugs Ltd (AARTIDRUGS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Aarti Drugs reported 9% revenue growth, reaching INR 679 crores in Q4 FY25, with EBITDA margins improving to 14%.
- Strong global API demand drove a 15.5% volume growth, primarily from exports.
- Standalone EBITDA margins reached 14.5% due to improved operating leverage and stable input costs.
- FY25 presented challenges with a 5% year-on-year revenue decline due to muted global demand and fluctuating raw material costs.
- Despite challenges, the company maintained a 12.6% EBITDA margin for FY25 and improved gross margins by over 200 basis points to 35.8%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.